Scienture Holdings, Inc. (SCNX) NASDAQ
0.39
+0.01889999(+5.08%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.39
+0.01889999(+5.08%)
Currency In USD
| Previous Close | 0.37 |
| Open | 0.38 |
| Day High | 0.41 |
| Day Low | 0.38 |
| 52-Week High | 2.6 |
| 52-Week Low | 0.24 |
| Volume | 175,751 |
| Average Volume | 3.02M |
| Market Cap | 6.03M |
| PE | -0.14 |
| EPS | -2.7 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 0.78 |
| Change | 0.02 |
SCIENTURE Broadens Commercial Access for REZENOPY™, Highest-Dose FDA-Approved Naloxone Nasal Spray, Through GPO Agreements Reaching Over 5,000 U.S. Institutions
GlobeNewswire Inc.
Mar 11, 2026 12:05 PM GMT
Expands institutional footprint with potential penetration of more than ~ 60% of the U.S. market, while expanding reach across EMS providers and rehabilitation centers U.S. naloxone market totals $141M with 9.4 million prescription units annually, re
SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
GlobeNewswire Inc.
Feb 03, 2026 1:05 PM GMT
Company highlights accelerating access and revenue growth for ARBLI™ and confirms REZENOPY™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 outlook and reports significant b
SCIENTURE Announces Issuance of Orange Book-Listable Patent Covering REZENOPY™, the Highest Dosage Naloxone HCl Nasal Spray Approved by the FDA for Life-Saving Opioid Overdose Emergency Treatment
GlobeNewswire Inc.
Jan 14, 2026 1:05 PM GMT
U.S. Naloxone Market: ~$154 million in annual sales and 9.3 million units annually COMMACK, NY, Jan. 14, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies